Cancer remains the leading cause of death from disease in children. Historically, in contrast to their adult counterparts, the causes of pediatric malignancies have remained largely unknown, with most pediatric cancers displaying low mutational burdens. Research related to molecular genetics in pediatric cancers is advancing our understanding of potential drivers of tumorigenesis and opening new opportunities for targeted therapies. One such area is fusion oncoproteins, which are a product of chromosomal rearrangements resulting in the fusion of different genes. They have been identified as oncogenic drivers in several sarcomas and leukemias. Continued advancement in the understanding of the biology of fusion oncoproteins will contribute to the discovery and development of new therapies for childhood cancers. Here we review the current scientific knowledge on fusion oncoproteins, focusing on pediatric sarcomas and hematologic cancers, and highlight the challenges and current efforts in developing drugs to target fusion oncoproteins.
Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy
- Views Icon Views
- Share Icon Share
- Search Site
Sara D. A. Angione, Alemayehu Y. Akalu, Jessica Gartrell, Elimika Pfuma Fletcher, Gilbert J. Burckart, Gregory H. Reaman, Ruby Leong, Clinton F. Stewart; Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy. The Journal of Pediatric Pharmacology and Therapeutics 1 September 2021; 26 (6): 541–555. doi: https://doi.org/10.5863/1551-6776-26.6.541
Download citation file: